Tixagevimab
Based on 1 Customer Validation
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.05%
- No. CAS: 2420564-02-7
- Peso molecular:146.48 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Human IgG1 kappa
Virus
Severe acute respiratory syndrome coronavirus 2
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
4.37406e+007 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized SARS-CoV-2 S Protein RBD (Omicron, B.1.1.529, His, HY-P74447) can bind Tixagevimab. The EC50 for this effect is 146.4 ng/mL.
Chemical Information
-
No. CAS 2420564-02-7
-
Appearance Liquid
-
Peso molecular 146.48 kDa
-
Color Colorless to light yellow
-
SMILES
[Tixagevimab]
-
Synonyms
AZD8895; COV2-2196
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)